SCHEIN AND ETHICAL HOLDINGS IN $32 MIL. LICENSING AND DEVELOPMENT DEAL
SCHEIN AND ETHICAL HOLDINGS IN $32 MIL. LICENSING AND DEVELOPMENT DEAL for the "development of a portfolio of oral controlled- release and/or transdermal products." With the Sept. 1 joint venture announcement, Florham Park, N.J.-based Schein moves into alternative drug delivery systems development with Godmanchester, England-based Ethical Holdings.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth